O5 Adoption Leads to Bullish Views Around Insulet Corporation (PODD)

Insulet Corporation (NASDAQ:PODD) is one of the 10 best healthcare equipment stocks to buy according to hedge funds.

On February 4, Stifel lowered its price target on Insulet Corporation (NASDAQ:PODD) from $370 to $350. The firm reiterated a Buy rating on the shares, with a revised upside of almost 45%. The revision was part of its broader 2026 estimates for dental, diabetes, and aesthetics segments.

On January 27, Mathew Blackman from TD Cowen downgraded his rating on Insulet Corporation (NASDAQ:PODD) from Buy to Hold. The analyst estimated a target price of $294, implying an upside potential of more than 21%.

Blackman believes the company carries a solid momentum, supported by O5 gaining patient adoption and driving sector-leading growth. While the company benefits from strengths in product design and pharmacy channel access, he cautioned that competitive advantages may narrow as the market evolves. Even though the company still has growth opportunities and a visible pipeline, the firm expects modest upside.

Insulet Corporation (NASDAQ:PODD) focuses on manufacturing and selling insulin management systems through the Omnipod platform. It offers a disposable tubeless pump called Omnipod Insulin Management System, whose design is specific to insulin-dependent diabetes. The company’s strategy revolves around high-volume automated manufacturing in the US and Malaysia, and contract manufacturing in China.

While we acknowledge the potential of PODD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This article is originally published at Insider Monkey.